FindTrial
Sign In

DNA Methylation as a Biomarker for Cervical Adenocarcinoma Detection and Prognosis Monitoring and Determine the Effect of the Neoadjuvant therapy of locally advanced adenocarcinoma cervic

DNA Methylation as a Biomarker for Cervical Adenocarcinoma Detection and Prognosis Monitoring and Determine the Effect of the Neoadjuvant therapy of locally advanced adenocarcinoma cervic

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018931
Enrollment
Unknown
Registered
2018-10-17
Start date
2009-10-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cervical Carcinoma

Interventions

Gold Standard:Clinical outcome
Index test:DNA Methylation

Sponsors

HuNan Tumor Hospital, Gynecologic Oncology Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with adenosquamous or adenocarcinoma of the cervix; 2. FIGO stage IB2–IIB; 3. aged 18 and 75 years; 4. Eastern Cooperative Oncology Group (ECOG) perfor- mance status 0–2; 5. normal cardiac and respiratory functions; 6. absence of secondary malignancies.

Exclusion criteria

Exclusion criteria: (1) secondary malignancies; (2) previous history of radiotherapy or chemotherapy; (3) serious active and uncontrolled infection and/or serious concomitant systemic disorders or psychiatric diseases.

Design outcomes

Primary

MeasureTime frame
SEN, SPE, ACC, ROC;—

Countries

China

Contacts

Public ContactWang Jing

The affiliated cancer hospital of Xiangya School of

wangjing@hnszlyy.com+86 13875902083

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026